These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21476878)

  • 1. Chimeric proteins comprising the constant region of immunoglobulins for treating hemophilia B (WO2005001025).
    Taupin P
    Expert Opin Ther Pat; 2011 Jun; 21(6):967-70. PubMed ID: 21476878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged activity of factor IX as a monomeric Fc fusion protein.
    Peters RT; Low SC; Kamphaus GD; Dumont JA; Amari JV; Lu Q; Zarbis-Papastoitsis G; Reidy TJ; Merricks EP; Nichols TC; Bitonti AJ
    Blood; 2010 Mar; 115(10):2057-64. PubMed ID: 20056791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
    Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
    PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
    Powell JS; Pasi KJ; Ragni MV; Ozelo MC; Valentino LA; Mahlangu JN; Josephson NC; Perry D; Manco-Johnson MJ; Apte S; Baker RI; Chan GC; Novitzky N; Wong RS; Krassova S; Allen G; Jiang H; Innes A; Li S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Nugent K; Vigliani G; Brennan A; Luk A; Pierce GF;
    N Engl J Med; 2013 Dec; 369(24):2313-23. PubMed ID: 24304002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
    Powell JS; Apte S; Chambost H; Hermans C; Jackson S; Josephson NC; Mahlangu JN; Ozelo MC; Peerlinck K; Pasi J; Perry D; Ragni MV; Wang X; Jiang H; Li S; Cristiano LM; Innes A; Nugent K; Brennan A; Luk A; Allen G; Pierce GF; Robinson B
    Br J Haematol; 2015 Jan; 168(1):124-34. PubMed ID: 25208598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eftrenonacog Alfa: A Review in Haemophilia B.
    Hoy SM
    Drugs; 2017 Jul; 77(11):1235-1246. PubMed ID: 28646426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Half-life extension through albumin fusion technologies.
    Schulte S
    Thromb Res; 2009 Dec; 124 Suppl 2():S6-8. PubMed ID: 20109653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.
    Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
    J Med Econ; 2017 Apr; 20(4):337-344. PubMed ID: 27885871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors.
    Pochopien M; Tytuła A; Toumi M; Falk A; Martone N; Hakimi Z; Eriksson D
    Adv Ther; 2024 Jun; 41(6):2307-2323. PubMed ID: 38652439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.
    Fischer K; Kulkarni R; Nolan B; Mahlangu J; Rangarajan S; Gambino G; Diao L; Ramirez-Santiago A; Pierce GF; Allen G
    Lancet Haematol; 2017 Feb; 4(2):e75-e82. PubMed ID: 28159192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice.
    van der Flier A; Hong V; Liu Z; Piepenhagen P; Ulinski G; Dumont JA; Orcutt KD; Goel A; Peters R; Salas J
    Blood Coagul Fibrinolysis; 2023 Sep; 34(6):353-363. PubMed ID: 37577860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.
    Shapiro AD; Ragni MV; Valentino LA; Key NS; Josephson NC; Powell JS; Cheng G; Thompson AR; Goyal J; Tubridy KL; Peters RT; Dumont JA; Euwart D; Li L; Hallén B; Gozzi P; Bitonti AJ; Jiang H; Luk A; Pierce GF
    Blood; 2012 Jan; 119(3):666-72. PubMed ID: 22110246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eftrenonacog Alfa: A Review in Haemophilia B.
    Lamb YN; Hoy SM
    Drugs; 2023 Jun; 83(9):807-818. PubMed ID: 37081241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant FIXFc: a novel therapy for the royal disease?
    Valentino LA
    Expert Opin Biol Ther; 2011 Oct; 11(10):1361-8. PubMed ID: 21780945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates.
    Powell J; Shapiro A; Ragni M; Negrier C; Windyga J; Ozelo M; Pasi J; Baker R; Potts J; Li S; Mei B; Pierce GF; Robinson B
    Br J Haematol; 2015 Jan; 168(1):113-23. PubMed ID: 25209873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the toxicology, pharmacokinetics, and local tolerance of recombinant factor IX Fc fusion protein in animals.
    Dumont JA; Loveday KS; Light DR; Pierce GF; Jiang H
    Thromb Res; 2015 Aug; 136(2):371-8. PubMed ID: 25840744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.
    O'Donovan M; Bergin C; Quinn E; Singleton E; Roche S; Benson J; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; O'Donnell JS; O'Connell NM
    Haemophilia; 2021 Jul; 27(4):618-625. PubMed ID: 33939224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B.
    Guillet B; Yan S; Hooper B; Drelich D; Steenkamp J; Tomic R; Mancuso ME
    Adv Ther; 2024 Feb; 41(2):649-658. PubMed ID: 38070040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX.
    Metzner HJ; Weimer T; Kronthaler U; Lang W; Schulte S
    Thromb Haemost; 2009 Oct; 102(4):634-44. PubMed ID: 19806248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.
    Shapiro A
    Expert Opin Biol Ther; 2013 Sep; 13(9):1287-97. PubMed ID: 23930915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.